FDA approves Boehringer’s biosimilar adalimumab
The US Food and Drug Administration has granted US market authorisation to Boehringer Ingelheim’s biosimilar anti-TNFa-antibody adalimumab.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Apeiron bags €25m from EIB
Supported by the European Fund for Strategic Investments (EFSI), the European Investment Bank (EIB) has granted a €25m loan to the Austrian pediatric cancer specialist Apeiron Biologics AG to boost its pipeline of antibodies, fusion proteins and low molecular weight checkpoint inhibitors.
Implementation of EU Unitary Patent Court delaying
In mid-June, the German Federal Constitutional Court asked the German President not to sign legislation designed to implement the EU Unified Patent Court (UPC, EU Agreement 16351/12) and Unitary Patent (EU Regulation 1257/12). Now, there are hints for a further delay. The constitutional complaint behind the delay, rumoured to be brought up by a German life sciences IP expert, has led to a stop of hiring German judges for the UPC.
Daratumumab meets endpoint as first-line multiple myeloma therapy
Danish Genmab A/S’ anti-CD38 antibody daratumumab has met the endpoint of progression-free survival in an interim analysis of Genmab’s pivotal Phase III study aimed at receiving FDA approval as first-line therapy in multiple myeloma.
Macrophage Pharma backed by Merck Ventures
Merck Ventures has joined the Series A investor syndicate of the British immuno-oncology specialist Macrophage Pharma Ltd.
Parkinson’s: factor protects from neuron decay
Scientists at Swedish Karolinska Institute have identified a factor that supports growth of midbrain dopaminergic (mDA) neurons, the nerve cells that degenerate during of Parkinson’s disease.
Topas Therapeutics lands option deal with Eli Lilly
Evotec’s immunology spin-out Topas Therapeutics has inked a multi-year R&D collaboration with pharma major Eli Lilly. The initial focus of research, which will be financed by Eli Lilly, is on identification of antigens that specifically induce a T regulatory cell response in inflammatory and auto-immune disorders.
Medivir licenses HCV drug MIV-802 to Chinese Ascletis
Medivir AB has exclusively licenced Greater China development and commercialisation rights of its preclinical candidate drug MIV-802 to Chinese drug developer Ascletis Bioscience Co. Ltd.
Checkpoint modulation: Blocking the tumour’s immune evasion strategies
Belgian, Swiss, and US researchers have found a new way to boost efficacy in cancer immunotherapy. In mid-April, they reported that cancer cells actively block tumour infiltration of cytotoxic T cells, but that this process can be reversed using angiogenesis blockers. Some Big pharma companies have already jumped on the bandwagon of angiogenesis/PDL1 combination therapy.
Swedish reasearchers link up cancer survival to protein levels
Using a national supercomputer, Swedish researchers have analysed how protein expression of the 315 known cancer genes translates into cancer overall survival.